Chemorefractory rhabdomyosarcoma treated with radiotherapy, bevacizumab, statins and surgery and maintenance with bevacizumab and chemotherapy

Onkologie

Volumn 31, Issue 7, 2008, Pages 391-393

  Lindén, Ola ^a   Greiff, Lennart ^a   Wahlberg, Peter ^a   Vinge, Ellen ^a   Kjellén, Elisabeth ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bevacizumab; Chemotherapy; Cystitis; Hydroxymethylglutaryl CoA reductase inhibitors; Hyperbaric oxygenation; Radiotherapy; Rhabdomyosarcoma; Statins; Surgery

Indexed keywords

BEVACIZUMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IFOSFAMIDE; SIMVASTATIN; VINBLASTINE; VINCRISTINE;

ADJUVANT THERAPY; AMENORRHEA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CYSTITIS; CYSTOSCOPY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG POTENTIATION; DRUG WITHDRAWAL; DYSPHAGIA; EMBRYONAL RHABDOMYOSARCOMA; FEMALE; HEARING IMPAIRMENT; HEMATURIA; HEMORRHAGIC CYSTITIS; HUMAN; HYPERBARIC OXYGEN; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCLE DISEASE; PLASMAPHERESIS; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RISK ASSESSMENT; TREATMENT FAILURE; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MAXILLARY NEOPLASMS; ORAL SURGICAL PROCEDURES; RADIOTHERAPY; RADIOTHERAPY, ADJUVANT; RHABDOMYOSARCOMA; TREATMENT OUTCOME;

EID: 47049106124     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000137715     Document Type: Article

References (11)

1. Gerber HP, Kowalski J, Sherman D, Eberhard DA, Ferrara N: Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res 2000;60:6253-6258.
2. Gee MF, Tsuchida R, Eichler-Jonsson C, Das B, Baruchel S, Malkin D: Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid. Oncogene 2005;24:8025-8037.
3. Dimitroulakos J, Ye LY, Benzaquen M, Moore MJ, Kamel-Reid S, Freedman MH, Yeger H, Penn LZ: Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: Therapeutic implications. Clin Cancer Res 2001;7:158-167.
4. Backman JT, Kyrklund C, Kivisto KT, Wang JS, Neuvonen PJ: Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 2000;68:122-129.
5. Jones PH, Davidson MH: Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005;95:120-122.
6. Weiss JP, Boland FP, Mori H, Gallagher M, Brereton H, Preate DL, Neville EC: Treatment of radiation-induced cystitis with hyperbaric oxygen. J Urol 1985;134:352-354.
7. Franca CM, Caran EM, Alves MT, Barreto AD, Lopes NN: Rhabdomyosarcoma of the oral tissues - two new cases and literature review. Med Oral Patol Oral Cir Bucal 2006;11:E136-140.
8. Johnson BF, Clay TM, Hobeika AC, Lyerly HK, Morse MA: Vascular endothelial growth factor and immunosuppression in cancer: Current knowledge and potential for new therapy. Expert Opin Biol Ther 2007;7:449-460.
9. Kawata S, Yamasaki E, Nagase T, Inui Y, Ito N, Matsuda Y, Inada M, Tamura S, Noda S, Imai Y, Matsuzawa Y: Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 2001;84:886-891.
10. Katz MS, Minsky BD, Saltz LB, Riedel E, Chessin DB, Guillem JG: Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 2005;62:1363-1370.
11. Ferrara N, Chen H, Davis-Smyth T, Gerber HP, Nguyen TN, Peers D, Chisholm V, Hillan KJ, Schwall RH: Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 1998;4:336-340.